Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment
Open Access
- 27 January 2005
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 19 (3) , 449-455
- https://doi.org/10.1038/sj.leu.2403647
Abstract
The immunological bone marrow (BM) microenvironment plays a major role in controlling growth and survival of clonal plasma cells (PC); this might translate into different patterns of expression of molecules involved in immune responses on PC from different types of monoclonal gammopathies (MG). We have studied the expression of a group of nine such molecules on both BMPC and the plasma of 61 newly diagnosed MG patients (30 MG of undetermined significance (MGUS), 27 multiple myeloma (MM) and four plasma cell leukemia (PCL)) and five normal individuals. Clonal PC from all MG displayed significantly increased levels of CD56, CD86 and CD126, and decreased amounts of CD38 (Pβ2-microglobulin were abnormally highly expressed in MGUS, while CD40 expression was decreased in MM and PCL (Pβ2-microglobulin was found from MGUS to MM and PCL patients (P=0.03). In contrast, all groups showed similar surface and soluble amounts of CD126, CD130 and CD95, except for increased soluble levels of CD95 observed in PCL. Overall, those phenotypic differences are consistent with increased antigen presentation and costimulatory capacities in MGUS, which progressively deteriorate in malignant MG (MM and PCL).Keywords
This publication has 39 references indexed in Scilit:
- Advances in biology of multiple myeloma: clinical applicationsBlood, 2004
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal GammopathyThe Journal of Experimental Medicine, 2003
- Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanismsLeukemia, 2003
- β2-Microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cellsBlood, 2003
- Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interactionBlood, 2002
- Chronic B cell malignancies and bone marrow microenvironmentSeminars in Cancer Biology, 2002
- Multiple myeloma: evolving genetic events and host interactionsNature Reviews Cancer, 2002
- Human myeloma cells express the CD38 ligand CD31British Journal of Haematology, 1999
- Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas MoleculeScience, 1994